Niaspan Antitrust Injury Is 'Pure Speculation,' Judge Told
Plaintiffs pursuing class actions against AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. over allegedly improper pay-for-delay settlements aimed at barring generic versions of the cholesterol drug Niaspan from entering the market...To view the full article, register now.
Already a subscriber? Click here to view full article